Drug intelligence / Profile preview

CAN105

Development stage: Preclinical
Lead developer: CANbridge Pharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

CAN105 is a bispecific monoclonal antibody being developed by CANbridge Pharmaceuticals (also known as Beihai Kangcheng) for the treatment of hemophilia A. Hemophilia A is a rare hereditary hemorrhagic disorder caused by a deficiency or defect in clotting factor VIII (FVIII). As a bispecific antibody, CAN105 is designed to address the unmet medical needs of patients with hemophilia A, potentially by mimicking the cofactor function of FVIII in the coagulation cascade. The drug is currently in the preclinical stage of development and is part of CANbridge's pipeline of assets targeting rare diseases.

Targets

F10 (Factor Xa)Coagulation Factor IXa

Beyond the preview

Go deeper on CAN105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAN105.

Explore the full profile